The scam linked to the compensation that the state paid to Novartis on the influenza A vaccine<\/strong><\/p>\n L'investigation<\/strong>\u00a0of the carabinieri of the\u00a0Nas<\/strong>\u00a0Of\u00a0Florence<\/strong>\u00a0is coordinated by the Siena prosecutor's office and hypothesizes a scam in the context of the supply to the Ministry of Health of the vaccine againstinfluence<\/strong>\u00a0A(H1N1) of 2009. The detectives<\/strong>\u00a0suspect a scam connected to the\u00a0compensation<\/strong>\u00a0which in 2012 the state paid a\u00a0Novartis<\/strong>, to which, in 2010, following the 'all-clear' pandemic, the ministry had asked for the supply of the vaccine to be interrupted. The charge would consist in the fact that the\u00a0compensation<\/strong>\u00a0was calculated on the basis of the significantly inflated price\u00a0fictitious<\/strong>\u00a0from\u00a0Novartis<\/strong>\u00a0of a central component of the\u00a0Vaccine<\/strong>, the MF59 adjuvant. The cost would have been increased thanks to a number of\u00a0overbilling<\/strong>\u00a0among the companies from the group.<\/p>\n Investigations on the regularity of the price<\/strong><\/p>\n The searches ordered by\u00a0power of attorney<\/strong>\u00a0of Siena in the Novartis offices also have the purpose of verifying whether, in addition to the supply of the vaccine against H1N1, Focetria, there have also been irregularities in determining the price for the seasonal flu vaccine, Fluad. Both are produced by Novartis<\/strong>\u00a0and they were bought by the ministry. The two vaccines have Mf59 as an adjuvant. According to the indictment, in determining the damage suffered for the interruption of supplies of the H1N1 vaccine, the\u00a0Novartis <\/strong>allegedly inflated the price of the Mf59, with a mark-up of 500% (3,964 euros per liter instead of 660) thanks to intragroup overbilling between the Italian, American and German subsidiaries. According to the indictment, this system would have misled the members of the commission of the ministry of health for the compensation of the damage linked to Focetria. The investigators of\u00a0Nas<\/strong>\u00a0they suspect that this may have also happened with Aifa, which determined the price of Fluad.<\/p>\n In a note<\/span><\/a>,\u00a0Novartis<\/strong>\u00a0underlines that \u00abhis work is, and has always been, marked by full respect for the law<\/strong>\u00a0and the provisions in force" and "renew its willingness to cooperate fully with the authorities". The supply of the vaccine of\u00a0Novartis<\/strong>\u00a0to deal with the H1N1 (swine flu) pandemic al\u00a0ministry<\/strong>\u00a0from the Health<\/strong>\u00a0had already been at the center of\u00a0controversy<\/strong>\u00a0more than 4 years ago. In January 2010, the independent news magazine\u00a0Other economics<\/strong>\u00a0had in fact published the contract<\/span><\/a> between the company and the dicastery, hitherto "top secret", signed by theCEO<\/strong>\u00a0Of\u00a0Novartis<\/strong>\u00a0vaccines, Francesco Gulli<\/span><\/a>, and since then\u00a0general manager<\/strong>\u00a0<\/b>of the\u00a0ministry<\/strong>, Fabrizio Oleari, today president of the Higher Institute of Health. \u00abThe writing \u2013 explained the Altriconomy \u2013 dates back to 21 August 2009. The text regulates thepurchase<\/strong>\u00a0direct of 24 million doses of\u00a0Vaccine<\/strong>. Cost: 184 million euros, VAT included. Even the\u00a0Court of Auditors<\/strong>\u00a0had complained that this private writing between the\u00a0ministry<\/strong>\u00a0from the\u00a0Health<\/strong>\u00a0and the pharmaceutical multinational\u00a0Novartis<\/strong>\u00a0was covered by secrecy. The story is not all here; Always there\u00a0Court of Auditors<\/strong>\u00a0had talked about\u00a0conditions too<\/strong>\u00a0favorable to Novartis<\/strong>, including the absence of\u00a0penalties<\/strong>, the acquisition by the\u00a0ministry<\/strong>\u00a0of the risks and the\u00a0compensation<\/strong>\u00a0to the multinational for any losses.<\/p>\n Investigations in Turin and Rome<\/strong><\/p>\n It is not the first investigation concerning the\u00a0pharmaceutical house.<\/strong>\u00a0TO\u00a0Turin<\/strong>\u00a0it's at\u00a0Rome<\/strong>\u00a0investigated starting from the fine imposed by theAntitrust<\/strong>\u00a0to Roche et al\u00a0Novartis<\/strong><\/span><\/a>\u00a0for a\u00a0sign<\/strong>\u00a0which affected the sales of the main eye care products, Avastin and Lucentis\u00bb<\/p>\n Aug 11, 2014 \u2013 NEWS Blog <\/a>\u00a0<\/i><\/p>\n Memorandum: Paradox Novartis: from the vaccine business to 24 ISF (out of 27) fired<\/span><\/a><\/span><\/i><\/p>\n